NON-HODGKIN LYMPHOMA

This study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma that had spread or come back after treatment. The goal was to find a safe dose and see if the drug could shrink tumors. The trial was stopped early, so re…

This early-phase study tested whether combining two drugs, tafasitamab and parsaclisib, is safe and effective for adults with certain blood cancers (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that had come back or stopped responding to prior treatments. The study enrol…

This early-phase study tested an experimental oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had come back after prior treatment. The main goals were to check safety, how the drug moves through the body, and find the right dose. The study was te…

This early-phase trial tested a two-step radiation treatment for people with non-Hodgkin lymphoma that had come back or stopped responding to standard therapies. The approach uses a targeting molecule to deliver a radioactive payload directly to cancer cells. Only one person was …

This early-stage trial tested a new drug called GEN3017 in people with CD30-positive Hodgkin or non-Hodgkin lymphoma that had returned or stopped responding to other treatments. The main goal was to check safety and find the right dose. Only 9 people took part before the study wa…

This study tested a new drug called IPH6501 in people with a type of blood cancer (non-Hodgkin lymphoma) that had come back or stopped responding to other treatments. The goal was to see if the drug was safe and to find the best dose. The trial was stopped early after enrolling 2…

This study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It included 200 people and aimed to see how many survived one year after the transplant. The approach is intense and mean…

This study tested a new treatment called CTX110, which uses CRISPR gene editing to modify donor immune cells to attack cancer. It was for adults with B-cell cancers like non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that had come back or not responded to other treat…

This early-stage study tested an oral drug called HMPL-523 in 69 adults with lymphoma that had returned or stopped responding to other treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was stopped early, so re…

This early-stage study tested a new drug called AUR103 Calcium in 27 adults with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and see how the drug worked in the body. The trial was terminated early, so no final results are …

This study aimed to see if a simple, 5-minute daily breathing exercise using a handheld device, combined with a personalized workout plan, could improve heart health and fitness in people who have survived lymphoma. Only one person enrolled before the study was stopped, so no mea…